ErascaERAS
ERAS
About: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Employees: 129
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
83% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 29
50% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 18
27% more capital invested
Capital invested by funds: $503M [Q2] → $639M (+$136M) [Q3]
6% more funds holding
Funds holding: 125 [Q2] → 132 (+7) [Q3]
0.8% more ownership
Funds ownership: 82.06% [Q2] → 82.85% (+0.8%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 6 [Q2] → 3 (-3) [Q3]
78% less call options, than puts
Call options by funds: $102K | Put options by funds: $466K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
165%
upside
Avg. target
$5.67
200%
upside
High target
$6
217%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Alec Stranahan 17% 1-year accuracy 1 / 6 met price target | 165%upside $5 | Buy Upgraded | 7 Jan 2025 |
Jefferies Maury Raycroft 9% 1-year accuracy 1 / 11 met price target | 217%upside $6 | Buy Initiated | 18 Nov 2024 |
HC Wainwright & Co. Andres Maldonado 30% 1-year accuracy 14 / 46 met price target | 217%upside $6 | Buy Reiterated | 13 Nov 2024 |
Financial journalist opinion
Based on 6 articles about ERAS published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.
Positive
Seeking Alpha
6 days ago
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors.
Positive
Zacks Investment Research
1 week ago
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
1 week ago
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
2 weeks ago
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Positive
Zacks Investment Research
2 weeks ago
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Positive
Zacks Investment Research
2 months ago
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
2 months ago
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025
Neutral
GlobeNewsWire
2 months ago
Erasca to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.
Neutral
GlobeNewsWire
5 months ago
Erasca Reports Second Quarter 2024 Business Updates and Financial Results
In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors
Charts implemented using Lightweight Charts™